Composition containing a synergistic combination of amantadine and vitamin D

By combining memantine and vitamin D in a synergistic manner, with unit doses of less than 0.5 mg and 0.08 mg, the adverse side effects and loss of efficacy caused by high doses of memantine are resolved, achieving effective treatment of Alzheimer's disease at extremely low doses.

CN123124969APending Publication Date: 2026-11-17SINAPTIS NEUROSCIENCES INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202580028609.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-04-16
Filing Date
2025-04-15
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

In the treatment of Alzheimer's disease, high doses of memantine and vitamin D often cause adverse side effects, and the efficacy may be lost after a certain period of time. There is a need for a drug combination that can effectively prevent and treat neurodegenerative diseases, limit adverse side effects, and maintain efficacy.

Method used

Using a synergistic combination of memantine and vitamin D, with unit doses of less than 0.5 mg and 0.08 mg respectively, these drugs are prepared in various forms using pharmaceutically acceptable excipients for the prevention and treatment of neurodegenerative diseases, particularly Alzheimer's disease.

Benefits of technology

At extremely low doses, the combination of memantine and vitamin D showed significant neuroprotective effects, reducing the effective dose of memantine to 1/100 of its original dose, reducing adverse side effects and maintaining therapeutic efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This invention relates to compositions comprising a synergistic combination of ammonium nitrate and vitamin D, methods for preparing the same, and their use in the prevention and treatment of neurodegenerative diseases, particularly Alzheimer's disease.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This invention relates to compositions comprising a synergistic combination of ammonium nitrate and vitamin D, methods for preparing the same, and their use in the prevention and treatment of neurodegenerative diseases, particularly Alzheimer's disease.

[0002] Glutamate excitotoxicity is involved in acute neurological damage caused by ischemic and traumatic brain injury, as well as chronic neurodegeneration associated with Alzheimer's and Huntington's diseases. Excitotoxic neuronal death caused by overactivation of N-methyl-D-aspartate receptors (NMDA receptors or NMDARs) leads to calcium (Ca) deficiency. 2+ Excessive and continuous influx of these substances into the cells triggers a series of responses that lead to cell death, such as increased oxidative stress, inappropriate activation of proteases like calpains, and calcium depletion. 2+ Dysregulation of related pathways, mitochondrial damage, and apoptosis cascade.

[0003] Memantine (MEM) is a low-affinity, voltage-dependent, non-competitive NMDA receptor antagonist. It is currently used in combination with acetylcholinesterase inhibitors such as galantamine, donepezil, and rivastigmine for the treatment of Alzheimer's disease (Allgaier et al., Frontiers in Bioscience, 2014, Vol. 19, pp. 1345-1354). Because it is a low-affinity antagonist, it blocks NMDA receptors but is rapidly displaced from them, thus preventing prolonged blockage of NMDA receptor channels and the side effects on learning and memory observed in the presence of high-affinity NMDA antagonists (dissociative anesthetics, ketamine, and MK-801). Another advantage of memantine is that it only interacts with NMDA receptor channels when they are pathologically activated by excessively high glutamate concentrations in the synaptic cleft, as is the case in Alzheimer's disease (Masters et al., Nature Reviews / Disease primers, 2015, 1, pp. 1-18).

[0004] Cholecalciferol is generally considered to be a form of vitamin D, also known as vitamin D3. Cholecalciferol is essential for maintaining calcium and phosphorus homeostasis in the human body. In addition, cholecalciferol receptors (VDRs) and cholecalciferol activating enzymes have been found in various brain structures, particularly the hippocampus, prefrontal cortex, and amygdala (Adam et al., Clin Endocrinol Metab, February 2010, 95(2), pp. 471-478). Cholecalciferol can regulate various physiological processes in the brain, such as the regulation of brain-derived neurotrophic factor (BDNF) and other neurotrophic factors, neurogenesis, neuroplasticity, neuroprotection, and neuroimmune regulation (DeLuca et al., Neuropathology and Applied Neurobiology, 2013, 39(5), pp. 458-484; Koshkina et al., Nutrients, 2019, 11, p. 1726). When used alone, cholecalciferol has no proven efficacy in treating neurodegenerative diseases, particularly Alzheimer's disease.

[0005] Therefore, early drug therapy using substances that reduce glutamate excitotoxicity may be a good option for improving neuronal survival (and cognitive function), and may represent a promising treatment strategy for patients diagnosed with Alzheimer's disease, and more generally for patients with neurodegenerative diseases.

[0006] For example, patent FR2965178B1 describes a pharmaceutical composition comprising 5 mg to 20 mg of memantine hydrochloride and 800 IU to 2000 IU of cholecalciferol, which may be used to treat Alzheimer's disease. The patent suggests, but does not demonstrate, a potential synergistic effect between the two active ingredients, particularly the synergistic effect of vitamin D on memantine.

[0007] Patent application EP2363119A1 describes pharmaceutical compositions comprising 1 mg to 40 mg of memantine and 200 IU to 10,000 IU of vitamin D, or 5 µg to 250 µg of vitamin D (40 IU of vitamin D is equivalent to 1 µg of vitamin D). These compositions are described as potentially useful for treating Alzheimer's disease, but no results demonstrating this efficacy are provided.

[0008] Anweiler C. et al. (Neurobiology of Aging, 2014, 35, pp. 331-335) described the neuroprotective effect of a combination containing 1 µM memantine and 100 nM vitamin D in an in vitro model of glutamate-induced cortical cytotoxicity.

[0009] D. Charier et al. (Annales Françaises d'Anesthésie et de Réanimation 33S, 2014, A168–A173) described the synergistic effect of 1 mM memantine and 100 nM vitamin D in preventing neuronal death in a mouse neuron model cultured in a microfluidic environment and subjected to blood-induced stress.

[0010] Although the combination of memantine and vitamin D and its potential use in the treatment of Alzheimer's disease have been described, these active ingredients are used in high doses that can cause adverse side effects. Indeed, it is evident from various prior art publications that memantine, when administered alone, is effective in treating Alzheimer's disease at doses greater than 5 mg. For example, memantine-based medications for treating moderate to severe Alzheimer's disease, regardless of the manufacturer, contain doses of 10 mg or 20 mg of memantine. At such doses, memantine frequently causes adverse reactions such as drowsiness, dizziness, balance disorders, shortness of breath, headache, constipation, high blood pressure, and elevated transaminase levels.

[0011] Furthermore, it has been recognized that the receptor on which memantine acts, namely the NMDA receptor, may be internalized, thereby reducing the efficacy of memantine and leading to loss of efficacy after a certain period of treatment (Katherine W. Roche et al., Nature Neuroscience, 2001, Vol. 4, pp. 794-802).

[0012] Therefore, there is a need for pharmaceutical compositions that can overcome these drawbacks to effectively prevent and / or treat neurodegenerative diseases, particularly Alzheimer's disease, while limiting the adverse side effects that are commonly observed or may be observed when using memantine at doses of 5 mg or higher, and reducing or eliminating loss of efficacy.

[0013] This invention aims to meet this need.

[0014] According to a first aspect, the present invention relates to a pharmaceutical composition comprising a synergistic combination of memantine and vitamin D and at least one pharmaceutically acceptable excipient, wherein the composition is characterized in that the unit dose of memantine present in the composition is less than 0.5 mg, and the unit dose of vitamin D present in the composition is less than 0.08 mg.

[0015] According to a second aspect, the present invention relates to the use of the pharmaceutical composition in the prevention and / or treatment of neurodegenerative diseases, and in particular Alzheimer's disease.

[0016] According to a third aspect, the present invention relates to a combination formulation comprising at least two independent components, characterized in that the first component contains a unit dose of less than 0.5 mg of memantine and the second component contains a unit dose of less than 0.08 mg of vitamin D, for use simultaneously, separately or sequentially in the prevention and / or treatment of neurodegenerative diseases, particularly Alzheimer's disease.

[0017] Finally, according to a fourth aspect, the present invention relates to a method for preventing, inhibiting, delaying or treating neuronal degeneration, particularly neuronal degeneration associated with Alzheimer's disease, in a subject in need, characterized in that it comprises administering to the subject a pharmaceutical composition as defined in a first aspect of the invention or a combination preparation as defined in a third aspect of the invention.

[0018] In fact, as illustrated in the following examples, the inventors have discovered that the combination of memantine and vitamin D can significantly reduce the effective unit dose of memantine, which is commonly used to treat Alzheimer's disease. In particular, the inventors have demonstrated that when memantine is used in combination with vitamin D, the effective unit dose of memantine can be reduced to at least 1 / 100 of its original value.

[0019] Therefore, a first aspect of the present invention is a pharmaceutical composition comprising a synergistic combination of memantine and vitamin D, characterized in that the unit dose of memantine present in the composition is less than 0.5 mg, and the unit dose of vitamin D present in the composition is less than 0.08 mg.

[0020] At this unit dose, neither compound showed any effect on neuronal survival or protection of neurite networks.

[0021] In an advantageous embodiment of the invention, natriuretic peptide is present in the form of a salt, particularly in the form of a hydrochloride salt.

[0022] According to the present invention, vitamin D may be selected from vitamin D2 or ergocalciferol, vitamin D3 or cholecalciferol, vitamin D4 or 22-dihydroergocalciferol, vitamin D5 or glutarate, its derivatives, such as vitamin D6, i.e., an ethylated derivative of vitamin D4, or vitamin D7, i.e., a 24R-methylated derivative of vitamin D3, and their salts.

[0023] In another particularly advantageous embodiment of the invention, vitamin D is cholecalciferol.

[0024] According to a preferred embodiment of the invention, the unit dose of ammonium is about 5 µg to about 0.1 mg, and the unit dose of vitamin D is about 0.8 µg to about 8 µg.

[0025] Also according to a preferred embodiment of the invention, the molar ratio of the synergistic combination of styrax and vitamin D is 1:2 to 1:100, and more preferably 1:3.5 to 1:100.

[0026] According to the present invention, the term "pharmaceuticalally acceptable excipient" refers to any substance other than one or more active ingredients intended to impart consistency, taste, or color to a drug while avoiding any interaction with one or more active ingredients. The pharmaceutically acceptable excipients according to the present invention will be selected from conventional excipients known to those skilled in the art, depending on the desired drug form and route of administration, for administration to humans or animals.

[0027] The pharmaceutical compositions of the present invention can be any form of medicine suitable for local, regional, systemic, or continuous administration. Examples of routes of administration include: oral, sublingual, subcutaneous, parenteral, intramuscular, intravenous, nasal, rectal, or any other route of administration. Suitable forms of administration include oral forms such as tablets, soft capsules or hard capsules, powders, granules, and oral solutions or suspensions; sublingual, sublingual, nasal, and inhalation forms; subcutaneous, intramuscular, or intravenous forms; rectal forms; and implants.

[0028] According to a preferred embodiment of the present invention, the pharmaceutical composition is formulated for oral administration.

[0029] The pharmaceutical compositions of the present invention can be prepared by any technique known to those skilled in the art, particularly by mixing memantine and cholecalciferol with at least one pharmaceutically acceptable excipient.

[0030] As described above, the synergistic combination present in the pharmaceutical compositions of the present invention exhibits neuroprotective effects at extremely low doses of memantine, which are completely inactive when used alone. Therefore, the usable synergistic combination of memantine and vitamin D according to the present invention also has a superior therapeutic index compared to memantine alone.

[0031] The present invention also relates to a pharmaceutical composition comprising a synergistic combination of ammonium nitrate and vitamin D and at least one pharmaceutically acceptable excipient, as defined in the first aspect of the invention, for the prevention and / or treatment of degenerative diseases.

[0032] Among neurodegenerative diseases, Alzheimer's disease, dementias such as Lewy body dementia, frontotemporal dementia (FTD), and mixed dementia, as well as other neurodegenerative diseases such as Charcot's disease (also known as amyotrophic lateral sclerosis, or ALS) and progressive supranuclear palsy (PSP) are particularly noteworthy. Of these neurodegenerative diseases, this invention is especially specific to the treatment of Alzheimer's disease.

[0033] Memantine and cholecalciferol can be formulated together or mixed immediately before administration. In this case, they can be in a form suitable for combined administration for the prevention and / or treatment of neurodegenerative diseases, particularly Alzheimer's disease.

[0034] Therefore, a third aspect of the present invention is a combination formulation comprising at least two independent components, characterized in that the first component contains a unit dose of less than 0.5 mg of memantine and the second component contains a unit dose of less than 0.08 mg of vitamin D, for use simultaneously, separately or sequentially in the prevention and / or treatment of neurodegenerative diseases, particularly Alzheimer's disease.

[0035] Finally, a fourth aspect of the invention is a method for preventing, inhibiting, delaying, or treating neuronal degeneration, particularly neuronal degeneration associated with Alzheimer's disease, in a subject with such need, wherein the method comprises administering an effective amount of a pharmaceutical composition as defined in the first aspect of the invention or a combination preparation as defined in the third aspect of the invention.

[0036] According to this fourth aspect, for an adult weighing approximately 70 kg, a typical administration regimen includes administering the pharmaceutical composition as defined in the first aspect of the invention or the combination formulation as defined in the third aspect of the invention once or twice daily.

[0037] According to a specific embodiment of the invention, and when the method includes the administration of the combination formulation, the unit dose of memantine and the unit dose of vitamin D are preferably administered simultaneously, and more preferably simultaneously and orally.

[0038] Brief description of the attached figures

[0039] the following Figures 1 to 4 The present invention has been described in conjunction with the embodiments:

[0040] [ Figure 1 ] Figure 1A shows the effect of memantine alone on the survival of MAP-2 neurons in primary cultures of glutamate-damaged cortical neurons, according to the example. Results are expressed as a percentage relative to the control; mean ± standard deviation (n=4–6 per group). Control = 100% corresponding to glutamate-free medium. One-way ANOVA was performed followed by Fisher's LSD test. *p<0.05 was considered statistically significant compared to 20 µM glutamate. Figure 1 B shows the effect of memantine alone on the protective effect of glutamate-damaged primary cortical neuronal networks, according to the embodiments. Results are expressed as a percentage relative to the control; mean ± standard deviation (n=4–6 per group). Control = 100% corresponding to glutamate-free medium. One-way ANOVA was followed by Fisher's minimum significance test. *p<0.05 was considered significant compared to 20 µM glutamate.

[0041] [ Figure 2 ] Figure 2 A shows the effect of the combination of memantine (500 pM in 180 µL of medium) and cholecalciferol (5 nM to 80 nM in 180 µL of medium) on the survival of MAP-2 neurons in primary cultures of glutamate-damaged cortical neurons, according to the examples. Results are expressed as a percentage relative to the control; mean ± standard deviation (n = 4–6 per group). Control = 100% corresponding to glutamate-free medium. One-way ANOVA was followed by Fisher's minimum significance test. *p < 0.05 was considered statistically significant compared to 20 µM glutamate. Figure 2 B shows the effect of the combination of memantine (500 pM in 180 µL of medium) and cholecalciferol (5 nM to 80 nM in 180 µL of medium) on the protection of total neural networks in primary cultures of glutamate-damaged cortical neurons, according to the examples. Results are expressed as a percentage relative to the control; mean ± standard deviation (n = 4–6 per group). Control = 100% corresponding to glutamate-free medium. One-way ANOVA was followed by Fisher's minimum significance test. *p < 0.05 was considered significant compared to 20 µM glutamate.

[0042] [ Figure 3 ] Figure 3A shows the effect of the combination of memantine (1 nM in 180 µL of medium) and cholecalciferol (dose range of 5 nM to 80 nM in 180 µL of medium) on the survival of MAP-2 neurons in primary cultures of glutamate-damaged cortical neurons, according to the examples. Results are expressed as a percentage relative to the control; mean ± standard deviation (n = 4–6 per group). Control = 100% corresponding to glutamate-free medium. One-way ANOVA was followed by Fisher's minimum significance test. *p < 0.05 was considered statistically significant compared to 20 µM glutamate. Figure 3 B shows the effect of the combination of memantine (1 nM in 180 µL of medium) and cholecalciferol (dose range of 5 nM to 80 nM in 180 µL of medium) on the protection of total neural networks in primary cultures of glutamate-damaged cortical neurons, according to the examples. Results are expressed as a percentage relative to the control; mean ± standard deviation (n = 4–6 per group). Control = 100% corresponding to glutamate-free medium. One-way ANOVA was followed by Fisher's minimum significance test. *p < 0.05 was considered statistically significant compared to 20 µM glutamate.

[0043] [ Figure 4 ] Figure 4 A shows the effect of the combination of memantine (10 nM in 180 µL of medium) and cholecalciferol (dose range of 5 nM to 80 nM in 180 µL of medium) on the survival of MAP-2 neurons in primary cultures of glutamate-damaged cortical neurons, according to the examples. Results are expressed as a percentage relative to the control; mean ± standard deviation (n = 4–6 per group). Control = 100% corresponding to glutamate-free medium. One-way ANOVA was followed by Fisher's minimum significance test. *p < 0.05 was considered statistically significant compared to 20 µM glutamate. Figure 4 B shows the effect of the combination of memantine (10 nM in 180 µL of medium) and cholecalciferol (dose range of 5 nM to 80 nM in 180 µL of medium) on the protection of total neural networks in primary cultures of glutamate-damaged cortical neurons, according to the examples. Results are expressed as a percentage relative to the control; mean ± standard deviation (n = 4–6 per group). Control = 100% corresponding to glutamate-free medium. One-way ANOVA was followed by Fisher's minimum significance test. *p < 0.05 was considered statistically significant compared to 20 µM glutamate.

[0044] Example: Prevention of glutamate toxicity in neuronal cells using different concentrations of memantine, cholecalciferol, and the synergistic composition according to the present invention.

[0045] Glutamate excitotoxicity is a cause of neuronal death in acute neurological diseases, including neurodegenerative diseases. Loss of calcium homeostasis is a key mediator of glutamate-induced cell death. The inventors tested the ability of amantadine alone to prevent or reduce the toxic effects of glutamate on glutamate-damaged primary cortical neurons.

[0046] 1.1 Materials and Methods

[0047] 1.1.1 Primary culture of cortical neurons

[0048] All experiments were conducted in accordance with the U.S. National Institutes of Health's guidelines for the care and use of laboratory animals and in compliance with current EU regulations (Directive 2010 / 63 / EU). License number: B1301310.

[0049] Rat cortical neurons were cultured as described by Callizot et al. (J. Neurosc. Res. (2013), 91(5), 706-716). Pregnant rats (Wistar) at 15 days of gestation were euthanized by cervical dislocation after deep anesthesia in a CO2 chamber. Briefly, fetal rats were collected and immediately placed in ice-cold Leibovitz L15 medium containing 2% penicillin (10000 U / mL) and streptomycin (10 mg / mL) (PS) solution and 1% bovine serum albumin (BSA) solution. The cortex was treated at 37°C with trypsin and EDTA solution at a final concentration of 0.05% trypsin and 0.02% EDTA for 20 minutes. Dissociation was terminated by adding Dulbecco's Modified Eagle's Medium (DMEM) containing 4.5 g / L glucose, grade II DNAse I (final concentration 0.5 mg / mL), and 10% fetal bovine serum (FCS). Cells were mechanically dissociated by forcibly passing them three times through a 10 mL pipette tip. The cells were then centrifuged at 515 x g for 10 min at 4 °C. The supernatant was discarded, and the pellet was resuspended in a compositionally determined medium consisting of neurobasal medium supplemented with 2% B27, 2 mmol / L L-glutamine, 2% PS solution, and 10 ng / mL brain-derived neurotrophic factor (BDNF). Viable cells were counted in a Neubauer cell counting chamber using the trypan blue exclusion assay. Cells were seeded at a density of 25,000 cells per well in 96-well plates pre-coated with poly-L-lysine and cultured at 37 °C in an air (95%) / CO2 (5%) incubator.

[0050] To avoid any edge effects, the first and last columns, as well as the first and last rows of the culture plate, were not used for studies. Empty wells were filled with water. The culture medium was changed every two days.

[0051] 1.1.2 Test Compound and Glutamate Exposure

[0052] Pre-incubation: On day 13 of culture, memantine (SIGMA ALDRICH hydrochloride) and cholecalciferol (SIGMA ALDRICH) were diluted in 180 µL of medium as defined in section 1.1.1 to a final concentration of 1x and pre-incubated with primary cortical neurons for 1 hour, and then exposed to glutamate.

[0053] Glutamic acid treatment: On day 13 of culture, while the compounds (alone or in combination) are still present, glutamate is added and diluted to a final concentration of 20 µM in 180 µL of medium for 20 minutes. After 20 minutes, the glutamate is removed by washing, and a small amount of fresh medium containing the same 1x concentration of the test compounds is added, and the treatment continues for another 48 hours.

[0054] 1.1.3 Immunostaining: MAP-2 (neuronal survival and network)

[0055] MAP-2 is a neuronal biomarker found in neuronal cell bodies and neurites, and it can be used to study neuronal survival and the length of neurite networks.

[0056] 48 hours after adding glutamate, the cell culture supernatant was removed. Cells were fixed for 5 minutes at -20°C using a cold ethanol (95%) and acetic acid (5%) solution. Cells were washed twice with phosphate-buffered saline (PBS). Cells were permeabilized with PBS containing 0.1% saponin and 1% fetal bovine serum at room temperature, and nonspecific binding sites were blocked for 15 minutes.

[0057] The culture was then incubated for 2 hours with a mouse anti-microtubule-associated protein 2 (MAP-2) monoclonal antibody diluted 1:400 in PBS containing 1% fetal bovine serum and 0.1% saponin. The antibody was then detected using Alexa Fluor 488 goat anti-microtubule IgG (Molecular Probes) (diluted 1:400) in PBS containing 1% fetal bovine serum and 0.1% saponin at room temperature for 1 hour.

[0058] 1.1.4 Computer-Automated Analysis

[0059] For each condition, 30 images (representing the entire well area) were acquired per well at 20x magnification using ImageXpress® (Molecular Devices). All images were acquired using the same acquisition parameters. Based on these images, analysis was performed automatically using MetaXpress® (Molecular Devices).

[0060] The following data were measured:

[0061] - Total neuronal survival (number of MAP-2 positive neurons); data are expressed as the average number of neurons per well (30 images).

[0062] - Total neural network (MAP-2, in µm); data are represented as the average neural network length per well (30 images).

[0063] 1.1.5 Statistical Analysis

[0064] All values ​​are expressed as mean + / - SEM (standard error of mean). Statistical analysis was performed using one-way ANOVA, followed by Dunnett's or Fisher's minimum significance test. p < 0.05 was considered significant.

[0065] 1.1.6 Results

[0066] * The effect of memantine alone on glutamate-damaged cortical neurons. These results show... Figure 1 In A and 1B.

[0067] Glutamate stress induces loss of cortical neurons ( Figure 1 A) and atrophy of the total neurite network ( Figure 1 B).

[0068] Memantine alone exhibited neuroprotective effects, significantly improving neuronal survival at all tested concentrations between 50 nM and 10 µM (corresponding to doses of 0.009 nmol to 0.0018 µmol per well in 180 µL of medium). Furthermore, significant protective effects on neurite networks were observed at concentrations between 100 nM and 10 µM (corresponding to doses of 0.018 nmol to 0.0018 µmol per well in 180 µL of medium). Only the two lowest concentrations (500 pM and 10 nM, corresponding to doses of 0.09 pmol and 0.0018 nmol per well in 180 µL of medium) showed no activity.

[0069] When memantine was used alone, dose-dependent neuroprotective effects (survival and neurite network protection) were observed.

[0070] * Effects of the synergistic combination of memantine and cholecalciferol on glutamate-damaged cortical neurons

[0071] These results show Figure 2 A, Figure 2 B Figure 3 A, Figure 3 B Figure 4 A and Figure 4 C.

[0072] The first three inactive concentrations of memantine were selected: 500 pM, 1 nM, and 10 nM (corresponding to doses of 0.09 pmol, 0.00018 nmol, and 0.0018 nmol per well, respectively, in 180 µL of medium). Each of these memantine doses was tested in combination with cholecalciferol at concentrations ranging from 5 nM to 80 nM (in 180 µL of medium), corresponding to similarly low doses of vitamin D, ranging from 0.0009 nmol to 0.0144 nmol per well.

[0073] Glutamate stress induces loss of cortical neurons ( Figure 2 A, Figure 3 A and Figure 4 A) and atrophy of the total neurite network ( Figure 2 B Figure 3 B and Figure 4 B).

[0074] These results indicate that:

[0075] - At a memantine concentration of 500 pM (0.09 pmol / well), and cholecalciferol concentrations of 35 nM (0.0063 nmol / well) and 50 nM (0.009 nmol / well), the memantine + cholecalciferol combination showed significant neuroprotective effects on neuronal survival and synaptic networks. Notably, this effect was not observed at cholecalciferol concentrations below 35 nM or above 50 nM.

[0076] - A significant neuroprotective effect on neuronal survival was observed in the combination of memantine and cholecalciferol at concentrations of 1 nM (0.00018 nmol / well), 20 nM (0.0036 nmol / well), and 35 nM (0.0063 nmol / well). Notably, this effect was not observed at cholecalciferol concentrations below 35 nM (0.0063 nmol / well) or above 50 nM (0.009 nmol / well).

[0077] - At a memantine concentration of 1 nM (0.00018 nmol / well), a significant neuroprotective effect on the synaptic network was observed with cholecalciferol concentrations of 20 nM (0.0036 nmol / well), 35 nM (0.0063 nmol / well), and 50 nM (0.009 nmol / well). Notably, this effect was not observed at cholecalciferol concentrations below 20 nM (0.0036 nmol / well) or above 50 nM (0.009 nmol / well).

[0078] - At a memantine concentration of 10 nM (0.0018 nmol / well) and a cholecalciferol concentration ranging from 20 nM (0.0036 nmol / well) to 80 nM (0.0144 nmol / well), the combination of memantine and cholecalciferol showed significant neuroprotective effects on neuronal survival and synaptic networks. Notably, this effect was not observed at cholecalciferol concentrations below 20 nM (0.0036 nmol / well) or above 80 nM (0.0144 nmol / well).

[0079] Therefore, regardless of the concentration of memantine tested (500 µM, 1 nM, or 10 nM, all three concentrations being inactive in neuroprotection on their own (corresponding to memantine doses of 0.09 µmol / well, 0.00018 nmol / well, and 0.0018 nmol / well, respectively), a synergistic combination with a similarly low concentration of cholecalciferol, i.e., 35 nM (i.e., 0.0063 nmol / well), can be obtained, resulting in a significant neuroprotective effect.

[0080] These results demonstrate that when memantine is combined with vitamin D, the effective dose of memantine, typically used alone to treat Alzheimer's disease, can be reduced to at least 1 / 100th of its original dose. Unwilling to be bound by any particular theory, the inventors believe these results are due to novel mechanisms of action, which may include, in particular, stimulation of a subunit of the NMDA receptor that differs from the subunit typically activated by higher doses of memantine, or morphological changes in the receptor itself, and / or better utilization of calcium ions.

Claims

1. A pharmaceutical composition comprising a synergistic combination of memantine and vitamin D, and at least one pharmaceutically acceptable excipient, characterized in that the unit dose of memantine present in the composition is less than 0.5 mg, and the unit dose of vitamin D present in the composition is less than 0.08 mg or equal to 0.08 mg.

2. The composition according to claim 1, characterized in that... The melanin exists in the form of a salt, particularly in the form of a hydrochloride salt.

3. The composition according to claim 1 or 2, characterized in that... The unit dose of the memantine is from 5 µg to 0.1 mg, and the unit dose of the vitamin D is from 0.8 µg to 8 µg.

4. The composition according to any one of claims 1 to 3, characterized in that The molar ratio of the synergistic combination of styrax and vitamin D is 1:2 to 1:

100.

5. The composition according to any one of claims 1 to 4, characterized in that... The vitamin D mentioned is cholecalciferol.

6. A pharmaceutical composition according to any one of claims 1 to 5, for the prevention or treatment of neurodegenerative diseases.

7. The pharmaceutical composition for use according to claim 6, characterized in that... The neurodegenerative disease mentioned is Alzheimer's disease.

8. A combination formulation comprising at least two separate components, characterized in that the first component contains a unit dose of less than 0.5 mg of memantine and the second component contains a unit dose of less than 0.08 mg of vitamin D, for use simultaneously, separately or sequentially in the prevention and / or treatment of neurodegenerative diseases, particularly Alzheimer's disease.

Citation Information

Patent Citations

  • New pharmaceutical composition suitable for treating persons affected by neurodegenerative or neurovascular diseases

    EP2363119A1